Ethambutol

Ethambutol


ETHAMBUTOL

INTRODUCTION:

  • One of the first-line anti-tubercular drug.
  • Given in combination with Isoniazid, Rifampin & Pyrazinamide.

MECHANISM OF ACTION:

  • Selectively bacteriostatic active against Mycobacterial group including Mycobacterium avium complex (MAC).
  • Inactive against other bacterial types.
  • Inhibits mycobacterial arabinosyl transferases (Encoded by embAB gene).
  • Arabinosyl transferases essential for polymerization reaction of arabinogalactan, an essential component of mycobacterial cell wall.

RESISTANCE:

  • Due to mutations resulting in Emb gene product overexpression or within emb B structural gene.

PHARMACOKINETICS:

Absorption

  • Bioavailability: ~80%
  • Peak plasma time: 2-4 hr

Distribution

  • Widely throughout body.
  • Concentrated in kidneys, lungs, saliva, & RBC’s.

CSF:blood level ratio: 

  • 0% (normal meninges); 25% (inflamed meninges)
  • Protein binding: 20-30%

Metabolism

  • Hepatic (20%) to inactive metabolite.
  • Not a hepatotoxic antitubercular drug.

Elimination

  • Half-life elimination: 2.5-3.6 hr; 
  • In end-stage renal disease – 7-15 hr.
  • Hence, requires dose adjustment in renal conditions.
  • Excretion: ~50% urine; ~50% faeces as unchanged drug.

Pregnancy & Lactation

  • Pregnancy Category: B
  • Lactation: Enters breast milk; use with caution 

USES:

Used along with other medications to treats number of infections including:

  • Tuberculosis, 
  • Mycobacterium avium complex (MAC
  • Mycobacterium kansasii.
  • Under RNTCP, for diagnosis of MDR TB, currently, drug sensitivity testing is done for Rifampicin, Isoniazid and Ethambutol.

CONTRAINDICATIONS:

  • Optic neuritis.
  • In young children unable to report visual effects.
  • Hypersensitivity.

MONITORING PARAMETERS

  • Ophthalmologic exam
  • Platelet count
  • Serum creatinine/BUN
  • Serum uric acid

ADVERSE REACTION:

  • Acute gout/hyperuricemia.
  • Due to interference with urate excretion.
  • Abdominal pain
  • Anaphylaxis.
  • Confusion.
  • Disorientation.
  • Fever.
  • Headache.
  • LFT abnormalities.
  • Malaise & nausea.
  • Optic neuritis – Most important.
  • Is a dose & duration of therapy dependent toxicity.
  • Symptoms may include decreased acuity, colour blindness(green colour) or visual defects.
  • Usually are reversible with discontinuation.
  • Peripheral neuritis.
  • Rash.

DRUG INTERACTIONS:

  • Aluminium hydroxide  – Reduce rate or extent of ethambutol absorption. 
  • At least 4 hours should elapse between doses of aluminium hydroxide-containing antacids & ethambutol.

BCG vaccine:

  • Ethambutol may interfere with development of an immune response following Bacillus Calmette-Guerin vaccine, BCG. 
  • Vaccine is live & sensitive to commonly used antituberculosis agents (e.g., isoniazid, ethambutol, rifampin).
Exam Question
 
  • Ethambutol is not a hepatotoxic antitubercular drug.
  • Ethambutol is bacteriostatic.
  • Under the RNTCP, for diagnosis of MDR TB, currently, drug sensitivity testing is done for Rifampicin, Isoniazid and Ethambutol.
  • In ethambutol toxicity, there will be loss of ability to see green colour.
  • Retrobulbar neuritis is seen with ethambutol. 
  • Hyperuricemia is seen with ethambutol.
  • Ethambutol is avoided in children as it causes visual disturbance
  • Antitubercular drug causing gout is ethambutol.
Don’t Forget to Solve all the previous Year Question asked on Ethambutol

Leave a Comment

Discover more from New

Subscribe now to keep reading and get access to the full archive.

Continue reading

👨‍⚕️
Chat Support ❌